TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma

Summary

This is a prospective one arm phase II clinical study to evaluate the efficacy and safety of TQB2450 (PD-L1 inhibitor), anlotinib combined with oxaliplatin and capecitabine in patients with unresectable locally advanced, recurrent or metastatic gastric cancer or adenocarcinoma of the gastroesophageal junction.

Timeline

Start

2021-05-10

Primary completion

2024-12-01

Completion

2024-12-01

Publications

• Bie L, Wei C, Luo S, Dong S, Gu Z, Ma Y, Xia Q, Zhang H, Li J, Deng W, Li N. Benmelstobart plus anlotinib and chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: A phase 2 study. Cell Rep Med. 2025 Jun 17;6(6):102145. doi: 10.1016/j.xcrm.2025.102145. Epub 2025 May 22.

Drugs

Indications